Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study
机构：[1]Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China北京朝阳医院[2]Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China[3]Henan Prov Peoples Hosp, Zhengzhou, Peoples R China[4]Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China[5]Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China[6]China Japan Friendship Hosp, Beijing, Peoples R China[7]Inner Mongolia Med Univ, Affiliated Hosp, Hohhot, Peoples R China[8]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China河北大学附属医院[9]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[10]Capital Med Univ, Chao Yang Hosp, Dept Hematol, Beijing, Peoples R China北京朝阳医院
第一作者机构：[1]Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Aijun,Fu Rong,Zhu Zunmin,et al.Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study[J].CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.2022,22:S177-S177.
APA：
Liu, Aijun,Fu, Rong,Zhu, Zunmin,Zhuang, Junling,Bao, Li...&Chen, Wenming.(2022).Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA,22,
MLA：
Liu, Aijun,et al."Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study".CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 22.(2022):S177-S177
